When a Patient Declines Psilocybin-Assisted Therapy After Explanation, Is That Really a Failure?

A recent implementation study by Dorval and colleagues examined the real-world introduction of psilocybin-assisted therapy in palliative oncology. The topic is important. Patients with advanced cancer may experience profound existential distress, fear of dying, loss of meaning, and psychological suffering that conventional care does not always adequately address. It is understandable that clinicians, researchers, and patients are interested in new therapeutic possibilities.

My concern is not with the value of studying psilocybin-assisted therapy in this setting. On the contrary, careful implementation studies are needed. The issue is more specific: how should patient hope be handled when a therapy is both medically promising and culturally powerful?

In the study by Dorval and colleagues, favorable professional attitudes, regulatory pathways, and estimated costs did not translate into clinical uptake. After one year, no patient had received psilocybin-assisted therapy. One patient declined treatment after learning more about the institutional protocol and conditions of administration.

This detail is easy to read as a problem of implementation. A patient was referred, learned more, and then did not proceed. But I think it can also be read in a different way.

Declining after explanation may not be a failure. It may be an ethical success.

In palliative oncology, psilocybin-assisted therapy should not be evaluated only through evidence, cost, regulatory access, and workflow. These factors matter. But they are not enough. For patients with advanced cancer and existential distress, several questions come before implementation metrics: Was the patient’s hope genuinely heard? Was the patient’s safety protected? Was the intervention ethically bounded?

A request for psilocybin-assisted therapy may mean many different things.

It may express fear of dying. It may express a desire for meaning. It may express hope for psychological relief. It may reflect interest in a transformative or spiritual experience. It may arise from dissatisfaction with conventional care. It may also be shaped by cultural associations with psychedelic drugs, including countercultural meanings.

These possibilities should not simply be accepted or rejected as a single “patient preference.” They need to be clarified.

This is especially important because psilocybin-assisted therapy is not just another drug intervention. It sits at the boundary of pharmacology, psychotherapy, spiritual experience, controlled-substance regulation, and end-of-life care. That boundary-crossing character is precisely what makes it clinically interesting. It is also what makes it ethically delicate.

Patients may encounter psilocybin-assisted therapy as an innovative treatment, a final option, a meaningful experience, or a promise of psychological transformation. But early explanation must make clear what the therapy cannot promise.

It cannot guarantee relief. It cannot guarantee a mystical or transformative experience. It may involve prolonged supervised administration. It may be contraindicated for medical or psychiatric reasons. It may involve difficult psychological experiences. It does not replace usual palliative, oncologic, or psychiatric care. It may also be delayed or restricted by institutional and regulatory procedures.

If these limits are explained only after expectations have already become inflated, refusal may become a late correction of hope. That is not ideal. Patients should be able to form, revise, and decline their preferences before hope becomes attached to an unrealistic image of the intervention.

This is where shared decision-making matters. Patient preferences are not simply collected. They are developed through the disclosure of options, benefits, harms, burdens, uncertainties, and alternatives. A patient’s initial hope is not necessarily the same as an informed, value-concordant preference.

The palliative care literature on hope is also helpful here. Hope is not only a prediction about the future. It may function as a truthful expectation, a coping resource, or a meaningful narrative. Clinicians therefore need to preserve hope without turning it into therapeutic overclaim.

That balance is difficult but essential. To dismiss hope is inhumane. To amplify hope without boundaries is unsafe.

For this reason, future implementation studies of psilocybin-assisted therapy in palliative oncology should include patient-centered ethical and safety indicators, not only professional attitudes, regulatory barriers, and costs.

Such indicators might include:

Was the patient’s initial hope documented before referral? Were benefits, limits, burdens, uncertainties, and alternatives explained early? Was it made clear that psilocybin-assisted therapy is not a substitute for usual care? Were medical and psychiatric contraindications assessed? Was there a plan for adverse psychological or physical events? Was continuation of usual palliative and oncologic care confirmed? Could the patient decline or stop without losing care? Were patient, caregiver, or patient-advocate perspectives included in the evaluation?

These questions are not secondary to implementation. They are part of implementation.

Making psilocybin-assisted therapy available is not the same as making it ethically usable. Access matters, but access alone is not the goal. The goal is to help patients transform an initial hope into an informed, safety-bounded, and value-concordant preference.

In that sense, the lesson is simple.

When a patient declines psilocybin-assisted therapy after receiving clear information, that should not automatically be seen as failed uptake. It may show that the patient was actually able to make a meaningful decision.

And in palliative care, that is not a small thing.

It is part of ethical care.

References

Dorval M, Audet-Croteau V, Chang S-L, Masse-Grenier M, Tremblay A, Bénard E, Chapdelaine A, Garel N, Guertin JR. Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation. Healthcare. 2026;14:1559. https://doi.org/10.3390/healthcare14111559

Xu Y. Boundaries and classification: the cultural logic of treating foreign medicine. Humanities and Social Sciences Communications. 2024;11:79. https://doi.org/10.1057/s41599-023-02484-2

Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared Decision Making: A Model for Clinical Practice. Journal of General Internal Medicine. 2012;27:1361–1367. https://doi.org/10.1007/s11606-012-2077-6

Olsman E, Leget C, Onwuteaka-Philipsen B, Willems D. Should palliative care patients’ hope be truthful, helpful or valuable? An interpretative synthesis of literature describing healthcare professionals’ perspectives on hope of palliative care patients. Palliative Medicine. 2014;28:59–70. https://doi.org/10.1177/0269216313482172

Disclosure

This essay is based on a Comment manuscript that was submitted to Healthcare but was not accepted for publication. No funding was received. I have no relevant financial or non-financial conflicts of interest to disclose. I used a large language model to assist with language refinement and structural editing. All arguments, interpretations, and final wording were reviewed and approved by me, and I take full responsibility for the content.

Psychedelic Therapy

Palliative Care

Medical Ethics